These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates. Muratore M; Quarta E; Grimaldi A; Calcagnile F; Quarta L Drug Des Devel Ther; 2011; 5():445-54. PubMed ID: 22087064 [TBL] [Abstract][Full Text] [Related]
4. [News on osteoporosis: good effect of treatment with diphosphonates]. Lakartidningen; 1997 Feb; 94(8):653-5. PubMed ID: 9072657 [No Abstract] [Full Text] [Related]
8. [Evaluation of the efficacy and tolerance of ibandronic acid in patients with osteoarthrosis in the knee joints concurrent with osteoporosis: a pilot study]. Alekseeva LI; Zaitseva EM; Sharapova EP; Taskina EA; Smirnov AV; Demin NV; Aleksandrova EN Ter Arkh; 2013; 85(5):30-6. PubMed ID: 23819336 [TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates in the treatment of osteoporosis. Principles and efficacy. Papapoulos SE Ann Med Interne (Paris); 2000 Oct; 151(6):504-10. PubMed ID: 11104931 [No Abstract] [Full Text] [Related]
11. [The successful development of bisphosphonates in the therapy of osteoporosis]. Fassbender WJ; Stumpf UC; Kurth A Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363 [TBL] [Abstract][Full Text] [Related]
12. Ibandronic acid: new drug. Osteoporosis: one tablet a month, but risk of a 'flu-like' syndrome. Prescrire Int; 2008 Feb; 17(93):11. PubMed ID: 18354857 [TBL] [Abstract][Full Text] [Related]